Welcome to our dedicated page for Solventum Corporation SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solventum Corporation (NYSE: SOLV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents help investors, analysts and other stakeholders understand Solventum’s financial performance, portfolio actions, capital structure and governance as it operates in the medical instruments and supplies sector.
Solventum uses current reports on Form 8-K to disclose a variety of material events. Examples include 8-K filings reporting quarterly financial results, such as third-quarter 2025 earnings, which incorporate press releases detailing segment performance, non-GAAP measures and updated guidance. Other 8-K filings describe material definitive agreements and their completion, such as the transaction agreement and subsequent closing of the sale of certain assets and liabilities related to Solventum’s purification and filtration business to Thermo Fisher Scientific Inc.
Additional 8-K filings cover capital markets and balance sheet activities, including the commencement, upsizing and pricing of cash tender offers for specified series of senior notes, and an underwriting agreement relating to the sale of shares by a selling shareholder. Governance and leadership changes, such as the appointment of a Chief Commercial Officer and the departure of a segment leader, are also reported on Form 8-K, along with information about related compensation and severance arrangements.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key points in clear language. This includes highlighting where Solventum discusses its “Transform for the Future” initiative, outlines risk factors, or provides pro forma financial information related to divestitures. The filings page is also a resource for tracking Solventum’s capital allocation strategy, including debt reduction, note tender offers and the authorization of a share repurchase program, as disclosed in its official documents.
Solventum Corporation is registering for resale 8,800,000 shares of its common stock held by the selling shareholder, 3M Company. The shares trade on the New York Stock Exchange under the symbol SOLV and the last reported sale price on August 13, 2025 was $74.38 per share. Solventum will not receive proceeds from the resale and the underwriter expects delivery on or about August 15, 2025. The prospectus supplement emphasizes substantial risks including operational, regulatory, supply chain, intellectual property, PFAS liabilities, clinical and reimbursement risks, standalone costs and risks related to the Spin-Off from the selling shareholder. The registration remains effective until the earlier of August 13, 2027 or when all registered shares are sold. Investors are directed to Solventum's incorporated SEC filings for further detail.
Solventum Corporation filed a Form S-3 prospectus dated August 13, 2025 to register for resale up to 34,369,190 shares of its common stock held by 3M Company. The selling shareholder will receive all proceeds from any sales; Solventum will not receive proceeds from this offering. The prospectus cites a last reported sale price of $72.09 per share on August 12, 2025 and states there were 173,387,798 shares outstanding as of July 31, 2025. The registration statement will be kept effective under a Registration Rights Agreement through August 13, 2027 or until all registered shares are sold.
The filing describes Solventum as a global healthcare company with a 70+ year history, spun off from 3M on April 1, 2024. Corporate features disclosed include authorized capital of 750,000,000 common shares and 50,000,000 preferred shares, one vote per common share, no preemptive rights, a classified board in effect until 2028, and indemnification and D&O insurance. The prospectus highlights material risk factors explicitly, including that future sales by 3M could adversely affect the market price, spin-off-related costs and tax risks, potential PFAS liabilities, supply chain and regulatory risks, and other operational and financial risks incorporated by reference into the filing.
Solventum disclosed unaudited pro forma condensed consolidated financial statements reflecting a previously announced Transaction with Thermo Fisher Scientific to sell Solventum's purification and filtration business, as amended to exclude the drinking water filtration business. The amended agreement reduces the expected cash consideration from approximately $4.10 billion to approximately $4.00 billion, with closing price subject to customary adjustments.
The pro forma balance sheet is presented as if the Transaction occurred on June 30, 2025 and pro forma income statements assume the Transaction occurred on January 1, 2024 for periods shown. The filing notes the pro forma statements are illustrative, prepared under Article 11 of Regulation S-X, and do not reflect certain items including the Company’s intended use of net proceeds or potential corporate overhead reallocations related to the divestiture. The pro forma statements are filed as Exhibit 99.1.
Solventum Corporation received a Schedule 13G disclosure from Independent Franchise Partners, LLP, a United Kingdom investment adviser, reporting beneficial ownership of 10,141,066 common shares, representing 5.86% of the outstanding class. The filing covers the issuer's common stock and identifies the reporting person as an IA (investment adviser).
The statement shows sole voting power over 10,011,852 shares and sole dispositive power over 10,141,066 shares, and includes a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The disclosure notifies investors of a passive, material stake above the 5% reporting threshold.
Solventum has amended its transaction agreement with Thermo Fisher Scientific regarding the sale of its purification and filtration business. Key changes include:
- Excluding the drinking water filtration business from the sale
- Reducing purchase price from $4.10 billion to $4.00 billion
- Adding potential $75 million payment to Solventum upon future sale of water business or after 3 years
- Transaction still expected to close by end of 2025
Financial impact: The retention of water business will increase previously estimated annual EPS accretion beyond 15-20 cents, but reduce projected improvements in gross margin (was 200bps) and operating margin (was 100bps). Updated estimates will be provided during Q2 earnings call. Net proceeds will primarily be used for debt reduction. The amendment aims to decrease complexity and potentially accelerate closing timeline.